Rigel Pharmaceuticals (RIGL) Research & Development (2010 - 2026)

Rigel Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• In Q1 2026, Research & Development rose 38.41% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $36.5 million (up 41.66% YoY), while the FY2025 annual figure was $33.3 million, up 42.41% from the prior year.
• Research & Development was $11.7 million for Q1 2026 at Rigel Pharmaceuticals, up from $10.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $15.5 million in Q1 2022 to a low of $2.5 million in Q4 2022.
• Historically, Research & Development has averaged $8.3 million across 5 years, with a median of $6.8 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Research & Development slumped 81.21% in 2022, then soared 89.72% in 2025.
• A 5-year view of Research & Development shows it stood at $2.5 million in 2022, then grew by 27.44% to $3.2 million in 2023, then jumped by 76.77% to $5.6 million in 2024, then jumped by 89.72% to $10.7 million in 2025, then advanced by 9.27% to $11.7 million in 2026.
• The last three Research & Development figures came in at $11.7 million (Q1 2026), $10.7 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.